Citi analyst Jason Cassorla raised the firm’s price target on HCA Healthcare to $293 from $280 and keeps a Buy rating on the shares post the Q4 results. The analyst sees potential upside to estimates on volume/labor improvement and payor mix benefits on Medicaid redeterminations, among other considerations.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HCA:
- HCA Healthcare sees FY23 EPS $16.40-$17.60, consensus $18.23
- HCA Healthcare reports Q4 EPS $4.64, consensus $4.78
- HCA Healthcare price target raised to $296 from $237 at UBS
- HCA Healthcare price target raised to $270 from $240 at Truist
- HCA Healthcare price target raised to $275 from $240 at Deutsche Bank
